Mankind Pharma announced its consolidated financial results for the third quarter and nine months ended December 31, 2025, reporting steady growth driven by improved performance in its domestic pharmaceutical business and consolidation of its BSV portfolio.

The company posted a year-on-year revenue growth of 11.5 percent, with adjusted EBITDA margins of 25.9 percent. The performance was primarily supported by stronger domestic formulations growth and the integration of BSV operations.

Rajeev Juneja, vice chairman and managing director of Mankind Pharma, said the company continued to strengthen its position in the chronic therapy segment. Mankind’s chronic market share rose by 200 basis points year-on-year to 39.3 percent, led by robust growth of 16.7 percent in the cardiac segment and 14.4 percent in anti-diabetes therapies.

The company’s over-the-counter (OTC) business also showed signs of recovery, recording a 5.2 percent growth in the third quarter of FY26, compared with a decline of 2.6 percent in the previous quarter. Juneja noted that growth in the OTC segment is expected to improve further in the coming quarters.

Commenting on the BSV business, Juneja said growth initiatives are progressing well, with the segment delivering strong double-digit growth during the quarter. He added that the company remains confident of achieving long-term sustainable growth, anchored by four key pillars: a stable base business, a fast-growing specialty chronic portfolio, a high-potential OTC segment, and a super-specialty BSV portfolio.